CEMP Cempra Inc

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into Cempra Inc. And Encourages Investors To Contact The Firm For Additional Information

STEVENSON, Md.--(BUSINESS WIRE)--

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into Cempra Inc. (“Cempra” or the “Company”) (NASDAQ: CEMP). The firm’s investigation is focusing on whether the Company and/or its officers and directors violated state or federal securities law.

On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review on its website of Cempra’s drug, solithromycin, to treat community-acquired bacterial pneumonia highlighting a significant safety signal for hepatotoxicity. On this news, shares of CEMP fell $9.71 per share or over 58% to trading at a low of $6.95 per share on November 2, 2016.

If you have suffered a loss in excess of $100,000 from investment in Cempra securities purchased from approximately August 1, 2016 through November 1, 2016, and would like to learn more about Brower Piven’s investigation, you may contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.

EN
02/11/2016

Underlying

CEMPCempra Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cempra Inc

 PRESS RELEASE
Free
CEMP CEMPRA INC

Melinta Therapeutics Announces Appointment of Christine Ann Miller as ...

Melinta Therapeutics Announces Appointment of Christine Ann Miller as President and Chief Executive Officer MORRISTOWN, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that its Board of Directors has appointed Christine Ann Miller as President and Chief Executive Officer and member of the board, effective August 3, 2020. In April of this year, Melinta became privately owned by affiliates of healthcare investment firm Deerfield Management Compan...

August 3, 2020 1 EN
GlobalData Department
  • GlobalData Department
EUR 221.13
CEMP CEMPRA INC

Cempra Inc (CEMP) - Pharmaceuticals & Healthcare - Deals and Alliances...

Summary Cempra Inc (Cempra), formerly Cempra Holdings LLC is a pharmaceutical company that develops antibacterials to the critical medical needs. The company offers products which include solithromycin and fusidic acid. It offers solithromycin, an oral and intravenous fluoroketolide. Cempra offers fusidic acid which is active against gram-positive organisms including MRSA. The company offers macrolides which are antimicrobial drugs that are active against aerobic and anaerobic gram-positive coc...

09/27/18 September 27, 2018 45 EN
 PRESS RELEASE
Free
CEMP CEMPRA INC

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Cempra, ...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Cempra, Inc. (NASDAQ:CEMP) between October 22, 2015 and November 1, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Middle District of North Carolina. To get more information go to: http://www.zlk.com/pslra/cempra-inc or contact Joseph E. Levi, Esq. either via email at jlev...

January 3, 2017 1 EN
 PRESS RELEASE
Free
CEMP CEMPRA INC

GPM Reminds Investors of the January 3 Deadline in the Class Action La...

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the January 3, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Cempra, Inc. (“Cempra” or the “Company”) (NASDAQ: CEMP) securities between May 1, 2016 and November 1, 2016, inclusive (the “Class Period”). Cempra investors have until January 3, 2017 to file a lead plaintiff motion. The Complaint filed in this lawsuit alleges that throughout the Class Period, Defendant...

December 30, 2016 1 EN
 PRESS RELEASE
Free
CEMP CEMPRA INC

CEMP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareh...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Middle District of North Carolina on behalf of investors who purchased Cempra, Inc. (NASDAQ:CEMP) securities between October 22, 2015 and November 1, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/cempra. There is no cost or obligation to you. According to the complaint, during the Class Period, Cempra made false and/or misleading statements and/or failed to d...

December 27, 2016 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch